Weekly Recap: Phase III savolitinib+osimertinib results and HMPL-A830 deal
Hutchmed China Limited (US) (NASDAQ:HCM) will unveil Phase III data at ESMO 2026 showing savolitinib+osimertinib improved PFS and OS in EGFR—mutant NSCLC with MET alterations, while HCM struck an exclusive global (ex—China/HK/Macau/Taiwan) deal with a GSK subsidiary for HMPL-A830 and will lead its…